RecruitingNCT06596746
Neurological
Progressive Supranuclear Palsy
Also known as PSP, Richardson syndrome, PSP-RS, Steele-Richardson-Olszewski syndrome
Progressive supranuclear palsy (PSP) is a rare neurodegenerative tauopathy characterized by 4-repeat tau (4R-tau) accumulation in neurons and glia of the brainstem, basal ganglia, and cerebral cortex. The Richardson syndrome (PSP-RS) phenot
ORPHA:683 ↗Gene MAPT (risk haplotypeGene rarely causative)Prevalence 1-5 per 10,000 (Orphanet)Onset AdultSporadic (MAPT risk haplotype, H1)
29
studies recruiting now
as of 7 Sept 2026
169
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
1 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT03225144
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RecruitingNCT07798700
Biofluid Research on Age-Related or Inherited Neurodegeneration
RecruitingPhase 2NCT07173803
The Progressive Supranuclear Palsy Clinical Trial Platform
RecruitingNCT04363684
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 29 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Progressive Supranuclear Palsy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: CurePSP Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative tauopathy characterized by 4-repeat tau (4R-tau) accumulation in neurons and glia of the brainstem, basal ganglia, and cerebral cortex. The Richardson syndrome (PSP-RS) phenotype is most common, featuring vertical supranuclear gaze palsy, early postural instability with falls, dysarthria, and cognitive decline. PSP is uniformly fatal, with a median survival of 5-7 years from symptom onset.
Common clinical features
Vertical supranuclear gaze palsyPostural instability and falls backwardDysarthria and dysphagiaCognitive and behavioral changesAxial rigidityMicrographiaEyelid apraxia
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Rivastigmine (Exelon)
Phase 3Riluzole (Exservan)
Phase 3Rasagiline
Phase 2/3Davunetide
Phase 2Ubidecarenone
Phase 2Tilavonemab
Phase 2Tertomotide
Phase 2Gosuranemab
+ 7 more in development
Before you apply
Things trial teams commonly ask about for Progressive Supranuclear Palsy. Not eligibility rules; those are set by each study.
- Movement Disorder Society PSP diagnostic criteria (probable or possible) must be met — vertical gaze palsy documentation is required
- CSF neurofilament light chain (NfL) and CSF total tau are biomarkers used in trial stratification
- Anti-tau therapies (ASOs, antibodies) are the primary investigational approaches — disease duration of <4 years is a common eligibility cut-off
- Functional status (PSP Rating Scale score) and mobility documentation are required baseline measures
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).